The Qfitlia approval in India, announced by Sanofi on 21 October 2026, gives eligible people with haemophilia A or B a new preventive option that works by lowering antithrombin instead of replacing the missing clotting factor. The Central Drugs Standard Control Organisation has granted marketing authorisation to Sanofi Healthcare for adults and adolescents aged 12 and older, with or without factor VIII or IX inhibitors. The company says routine prophylaxis can need as few as six injections a year. This report explains what the Qfitlia approval in India changes, how fitusiran differs from factor therapy and what the evidence does and does not show. It is general information and not medical advice.
Qfitlia approval in India: key takeaways
- India’s drug regulator has granted marketing authorisation for Qfitlia (fitusiran), according to Sanofi’s announcement of 21 October 2026.
- It is indicated to prevent or reduce bleeding episodes in people aged 12 and older with haemophilia A or B, including those with inhibitors.
- It is described as the first antithrombin-lowering therapy for routine prophylaxis, and it is not a clotting-factor replacement.
- Launch timing, price and availability were not stated in the reports we reviewed.
- Any decision on treatment belongs with a haemophilia specialist, who will consider safety monitoring, which is significant for this drug.
What the Qfitlia approval in India covers
According to published reports of the announcement, the authorisation applies to routine prophylaxis, which means regular treatment to prevent bleeds and not treatment of a bleed once it starts. The patient group is people aged 12 and older with haemophilia A or B, with or without inhibitors. Inhibitors are antibodies that make factor replacement less effective, so they are one of the hardest parts of haemophilia care. A Sanofi India rare-disease business head was quoted as saying the therapy could significantly expand access to prophylaxis in the country. We have not seen the approved Indian prescribing information, so the details below that depend on labelling come from the US regulator.
How Qfitlia works: the antithrombin approach
General background: haemophilia A is caused by a lack of clotting factor VIII, and haemophilia B by a lack of factor IX. Standard prophylaxis replaces the missing factor by injection, often several times a week, or uses other medicines that mimic it. Fitusiran takes a different route. It is a small interfering RNA that reduces the liver’s production of antithrombin, a natural brake on clotting. With less antithrombin, the body can make more thrombin, the enzyme that drives clot formation, which helps restore a balance even when factor VIII or IX is missing. Because it does not depend on a factor, the approach can in principle be used whether or not a person has inhibitors.
What the evidence behind the Qfitlia approval in India shows
The Indian reports link the approval to the phase 3 ATLAS clinical programme and say it showed clinically meaningful bleed protection across patient groups, without giving figures. The US Food and Drug Administration announcement describes two randomised trials in 177 male patients. Using antithrombin-based dosing, the estimated annualised bleeding rate fell by 73% in people with inhibitors, compared with on-demand bypassing agents, and by 71% in people without inhibitors, compared with on-demand factor concentrates. We have not matched those trials one-to-one to the ATLAS studies named in India. Both comparisons were against on-demand treatment, which is a different question from how fitusiran compares with regular factor prophylaxis.
Qfitlia approval in India: what as few as six injections a year means
Sanofi’s figure of as few as six injections a year is consistent with the US dosing description, which starts with a subcutaneous injection once every two months. The US regulator says the dose and frequency are adjusted using an antithrombin test, and a fixed monthly dose was not approved because it caused excessive clotting in some patients. The word as few as matters here. Some people may need more frequent dosing, and the Indian schedule has not been published in the reports we saw. Compared with factor products given several times a week, even six to twelve injections a year would be a large reduction in treatment burden.
Qfitlia approval in India: safety patients and doctors must weigh
The US label carries a boxed warning for thrombotic events and gallbladder disease, including some patients who needed gallbladder removal. It also warns of liver toxicity, with liver blood tests recommended at the start and monthly for at least six months after starting or after a dose increase. Common side effects include viral infection, nasopharyngitis and bacterial infection. Lowering antithrombin changes the balance of clotting, so doctors usually take extra care in people with other clotting risks. We could not confirm whether the Indian label mirrors these statements, and families should rely on their treating team for guidance.
What the approval changes for eligible patients
This section is our analysis. For patients who already receive prophylaxis, an injection every two months or so could reduce the practical burden of frequent infusions, venous access problems and missed doses. For people with inhibitors, who have fewer options, a non-factor therapy may matter more. These benefits are possibilities and not guarantees. Whether a particular person benefits depends on access, cost, monitoring facilities and clinical judgement, and none of those has been described for India. Authorisation also does not mean the product is on sale, since launch timing and pricing were not stated.
Access, cost and monitoring in India
General background: haemophilia care in India relies on a mix of government programmes, hospital treatment centres, charity support and out-of-pocket spending, and the availability of specialist centres varies by region. A therapy that needs antithrombin testing and regular liver checks depends on laboratory access, which could limit who can use it first. The World Federation of Hemophilia publishes information for patients and clinicians on care standards. We have not seen details of any Indian patient-access plan from Sanofi.
What is not disclosed
- The approval date and the full conditions attached to the authorisation.
- Indian launch timing, pricing and distribution.
- Numerical results from the ATLAS trials in the Indian reports.
- Whether Indian prescribing information mirrors the US warnings and testing requirements.
Risks and caveats on the Qfitlia approval in India
- Safety warnings in the US label include thrombotic events, gallbladder disease and liver toxicity.
- The trial figures cited are from the US regulator’s summary and compare with on-demand treatment.
- Company statements are Sanofi’s own and have not been independently verified.
- This is news reporting, not medical advice.
In our assessment, the Qfitlia approval in India is an important expansion of choice for people with haemophilia A or B, but its real value will depend on safety monitoring, cost and access, none of which has been described yet. See our wider pharmaceutical news coverage.
What to watch next after the Qfitlia approval in India
- Launch timing and pricing from Sanofi.
- Publication of the Indian prescribing information and monitoring requirements.
- Further regulatory announcements on the CDSCO website.
Frequently asked questions
What is the Qfitlia approval in India?
India’s drug regulator has authorised Sanofi’s Qfitlia (fitusiran) to prevent or reduce bleeding in people aged 12 and older with haemophilia A or B, with or without inhibitors.
How is Qfitlia different from factor replacement?
It lowers antithrombin to help the body make more thrombin, instead of supplying the missing factor VIII or IX.
How often is it injected?
Sanofi says as few as six injections a year; the US dosing starts at once every two months and is adjusted by testing.
How we reported this: we relied on published reports of Sanofi’s announcement of 21 October 2026 and the US regulator’s announcement, and we did not see the Indian prescribing information. Company statements and our analysis are labelled. Last updated: 22 October 2026. This article is news reporting and not medical advice.